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The envelope glycoprotein GP64 of Autographa californica nucleopolyhedrovirus (AcMNPV) is necessary and sufficient for the acid-induced
membrane fusion activity that is required for fusion of the budded virus (BV) envelope and the endosome membrane during virus entry. Infectivity
of the budded virus (BV) is neutralized by AcV1, a monoclonal antibody (MAb) directed against GP64. Prior studies indicated that AcV1
recognizes a conformational epitope and does not inhibit virus attachment to the cell, but instead inhibits entry at a step following virus
attachment. We found that AcV1 recognition of GP64 was lost upon exposure of GP64 to low pH (pH 4.5) and restored by returning GP64 to pH
6.2. In addition, the AcV1 epitope was lost upon denaturation of GP64 in SDS, but the AcV1 epitope was restored by refolding the protein in the
absence of SDS. Using truncated GP64 proteins expressed in insect cells, we mapped the AcV1 epitope to a 24 amino acid region in the central
variable domain of GP64. When sequences within the mapped AcV1 epitope were substituted with a c-Myc epitope and the resulting construct
was used to replace wt GP64 in recombinant AcMNPV viruses, the modified GP64 protein appeared to function normally. However, an anti-c-
Myc monoclonal antibody did not neutralize infectivity of those viruses. Because binding of the c-Myc MAb to the same site in the GP64
sequence did not result in neutralization, these studies suggest that AcV1 neutralization may result from a specific structural constraint caused by
AcV1 binding and not simply by steric hindrance caused by antibody binding at this position in GP64.
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The Autographa californica multicapsid nucleopolyhedro-
virus (AcMNPV) is a large double-stranded DNA virus
(approximately 134 kbp) that produces two virion phenotypes
during the infection cycle (Miller, 1997). One virion phenotype,
the occlusion-derived virion (ODV), is adapted for stability in
the environment and propagation of infection from animal to
animal through oral transmission and infection of the midgut
epithelial cells. In contrast, the other virion phenotype, the
budded virion (BV), is adapted for propagation of infection from
cell to cell throughout the animal after infection is established in
the midgut (Granados and Lawler, 1981; Keddie and Volkman,
1985; Keddie et al., 1989; Monsma et al., 1996; Volkman and
Goldsmith, 1984; Volkman et al., 1984). The major envelope⁎ Corresponding author. Fax: +1 413 480 4762.
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doi:10.1016/j.virol.2006.04.041protein of the BV is known as GP64 (Hohmann and Faulkner,
1983; Volkman and Goldsmith, 1984; Volkman et al., 1984).
GP64 is essential for cell-to-cell transmission of the virus in cell
culture and in the infected animal (Monsma et al., 1996). GP64
serves twomajor roles during virus entry. First, GP64 is involved
in host cell receptor binding (Hefferon et al., 1999), although the
cellular receptor has not yet been identified. Second, GP64
mediates the low-pH-triggered membrane fusion activity neces-
sary for release of the nucleocapsid into the cytosol during entry
by endocytosis (Blissard and Wenz, 1992; Kingsley et al., 1999;
Markovic et al., 1998; Monsma and Blissard, 1995; Plonsky et
al., 1999; Volkman and Goldsmith, 1985). GP64 is found in the
membrane as a homotrimer (Oomens et al., 1995), and it has
been hypothesized that GP64 changes conformation in response
to low pH. Aggregates of multiple GP64 trimers have been
identified in the membrane during membrane fusion (Markovic
et al., 1998). For many other well-studied viral membrane fusion
proteins, triggering of conformational changes in the fusion
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one of the best current models, conformational changes in the
trimeric fusion protein are believed to result in translocation and
subsequent interaction of two separate alpha helical domains,
forming a six-helix bundle structure in the trimeric fusion protein
(Kielian and Rey, 2006). While it is not known whether such a
structure forms during fusion mediated by GP64, it was pre-
viously demonstrated that a predicted alpha helix and an up-
stream hydrophobic region in the GP64 protein were important
for membrane fusion activity of GP64 (Kingsley et al., 1999;
Monsma and Blissard, 1995).
A monoclonal antibody, AcV1 (Hohmann and Faulkner,
1983), that neutralizes infectivity of AcMNPV BV is important
as a tool for understanding the function of the GP64 protein.
AcV1 is directed against the GP64 protein, and preincubation of
BV with AcV1 results in reductions in BV infectivity by 3–4
orders of magnitude (Hohmann and Faulkner, 1983; Volkman
and Goldsmith, 1985; Volkman et al., 1984). Studies of BV
attachment to host cells in the presence of AcV1 suggested that
AcV1 neutralization did not result from inhibition of BV
attachment but rather from a block in the ability of BV virions to
use the endocytic pathway, at a stage after initial viral adsorption
(Volkman andGoldsmith, 1985). AcV1 binds to native GP64 but
does not recognize denatured GP64 by standard Western blot
analysis (Hohmann and Faulkner, 1983), suggesting that AcV1
recognizes a conformational epitope. The purpose of the current
study was to begin to dissect the antigenic, structural and func-
tional topography of GP64 using this conformation-dependent
monoclonal antibody. To understand possible changes in GP64
conformation, we examined AcV1 binding to GP64 under con-
ditions of normal and low pH and using a series of truncated
GP64 constructs. We found that AcV1 binding to GP64 was pH-
dependent, suggesting that GP64 conformation is modulated in
response to pH. To identify the region of the GP64 protein
recognized by AcV1, we generated a series of truncated recom-
binant GP64 proteins in insect cells and used them to map the
AcV1 epitope. AcV1 binding was mapped to a sequence of 24
amino acids located in the central variable domain of the GP64
protein. Substitution of 11 amino acids in the AcV1 epitope with
a c-Myc epitope sequence abrogated binding of AcV1 to GP64,
confirming the AcV1 epitope. GP64 proteins containing the c-
Myc substitution were capable of fully rescuing an AcMNPV
gp64-knockout virus, and the resulting protein was recognized
by an anti-c-Myc MAb. However, the anti-c-Myc MAb did not
neutralize infectivity.
Results and discussion
The AcMNPV GP64 protein is a membrane fusion protein
that mediates viral entry by receptor-mediated endocytosis
(Blissard and Wenz, 1992; Hefferon et al., 1999; Hohmann and
Faulkner, 1983; Monsma et al., 1996; Volkman et al., 1984). In
the endosome, GP64 is believed to change conformation in
response to low pH and that change is believed to trigger GP64-
mediated membrane fusion activity. The anti-GP64 monoclonal
antibody AcV1 neutralizes infectivity of AcMNPV BV and
recognizes a conformational epitope in the native but notdenatured GP64 protein (Hohmann and Faulkner, 1983; Volk-
man et al., 1984). In prior studies using AcV1, low pH treatments
of GP64 on infected cells inhibited immunofluorescent detection
and fusion activity (Chernomordik et al., 1995). To confirm and
extend studies of GP64 conformation and to characterize AcV1
binding and inhibition of GP64 function, we used immunopre-
cipitation assays in combination with truncated and substituted
forms of GP64 to examine AcV1 binding under various con-
ditions and we mapped the AcV1 epitope.
Low pH treatment of GP64 results in loss of the AcV1 epitope
To examine AcV1 binding to GP64 under conditions of
neutral and low pH, wild-type and modified GP64 proteins were
immunoprecipitated under conditions of normal or low pH, pH
6.2 or 4.5, respectively. Because Sf9 cells are typically cultured
in media at pH 6.0–6.2 and AcMNPV infections are typically
performed at the same pH values, the pH value of 6.2 was
selected as the “normal” or “neutral” pH for GP64 conformation
studies. Cells expressing either wt GP64 or a GP64 protein with
an N-terminal c-Myc epitope tag (NTr1/21–512) were lysed and
GP64 was immunoprecipitated with either MAb AcV1 or a
control anti-c-Myc MAb (Fig. 1A, lanes 1, 4, and 7). To deter-
mine if the AcV1 epitope was present and available in various
conformations, the GP64 protein was incubated at various pH
values prior to antibody binding and immunoprecipitation.
When preincubated at pH 6.2, both wild-type GP64 and
c-Myc tagged GP64 were efficiently immunoprecipitated with
MAb AcV1. However, when preincubated at pH 4.5, neither
construct was recognized and immunoprecipitated by AcV1
(Fig. 1A, lanes 2 and 5). To determine if the observed effect
resulted from a general inability of monoclonal antibodies to
bind and immunoprecipitate GP64 at pH 4.5, an anti-c-Myc
MAb was used to immunoprecipitate the N-terminally c-Myc
tagged GP64 protein in a parallel experiment. The anti-c-Myc
MAb bound and immunoprecipitated the N-terminally tagged
GP64 protein at both pH 6.2 and 4.5 (Fig. 1A, lanes 7 and 8).
Thus, failure of AcV1 to bindGP64 at low pH (pH 4.5) is not due
to an intrinsic property of monoclonal antibody binding at pH
4.5 but appears to be due to a change in the availability of the
conformation-specific AcV1 epitope. To determine if the loss of
the AcV1 epitope at low pH was reversible, we exposed wt and
c-Myc tagged GP64 constructs to pH 4.5 for 30 min and then
returned the proteins to pH 6.2 and immunoprecipitated GP64
with AcV1. Although the efficiency of GP64 detection by this
method was slightly reduced, AcV1 recognition was restored by
returning GP64 to pH 6.2 after low pH treatment (Fig. 1A, lanes
3 and 6). Thus, the conformation-specific AcV1 epitope that is
lost when GP64 is denatured by SDS and beta-mercaptoethanol
treatment was also lost upon exposure to low pH. However, the
pH-induced change was reversible as the AcV1 epitope was
restored when the pH was returned to pH 6.2.
Low pH treatment of AcMNPV BV neutralizes infectivity
Because recognition of the AcV1 epitope was lost upon
exposure to pH 4.5 but was restored by incubation at pH 6.2, we
Fig. 1. (A) Immunoprecipitation of 35S-methionine-labeled GP64 constructs
with MAb AcV1 (lanes 1–6) and anti-c-Myc (lanes 7–8). Cells expressing wild-
type AcMNPVor NTr1(21–512) GP64 proteins were metabolically labeled with
35S-methionine. Cell lysates containing wild-type GP64 or NTr1(21–512)
proteins were subjected to various treatments (pH 6.2, pH 4.5 or pH 4.5 followed
by a shift to 6.2) then subjected to immunoprecipitation with MAb AcV1 or anti-
c-Myc and analyzed on an SDS-10% polyacrylamide gel. The diagram (bottom)
shows the construction of a control protein, N-terminally c-Myc tagged GP64,
NTr1(21–512) (SP, signal peptide; c-Myc, c-Myc tag; TM, transmembrane
domain; CTD, cytoplasmic tail domain). (B) Effect of low pH treatment on BV
infectivity. Wild-type AcMNPV budded viruses at pH 6.2 were adjusted to pH
4.5 with either PBS (pH 1.7) or Grace's medium (pH 2.1). The low-pH-adjusted
virus was incubated for 30 min at room temperature then returned to pH 6.2 by
addition of either PBS (pH 12.3) or Grace's medium (pH 9.6). Titers were then
determined by end-point dilution. Control BV preparations were similarly
treated with PBS or Grace's medium but at pH 6.2 only. The results represent the
average value of three separate replicate experiments.
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infectivity. We asked whether the previously reported inactiva-
tion of AcMNPV by low pH could be reversed by returning the
virus to neutral pH. Wild-type AcMNPV BV was treated for
30 min with PBS or Grace's medium adjusted to pH 4.5, then
the pH was readjusted to pH 6.2 and the virus infectivity was
determined. As a control, the same virus preparation was
exposed to PBS or Grace's media at pH 6.2 (instead of pH 4.5),
but otherwise treated identically. Exposure of AcMNPV BV to
pH 4.5 resulted in an approximately 1000-fold reduction in theinfectious titer (Fig. 1B). Similar results were obtained in three
replicate experiments. Thus, although the low-pH-induced
conformational change associated with AcV1 binding was
reversible, exposure to pH 4.5 appears to irreversibly neutralize
virus infectivity.
AcV1 epitope mapping with truncated GP64 proteins
To map the epitope recognized by AcV1, we generated a
series of truncated GP64 constructs for expression in insect
cells. We first constructed 9 baculovirus expression vectors that
encode and express soluble forms of GP64 that are C-terminally
truncated and tagged at the C-terminus with a V5 epitope and
6His. The construct names (CTr1(21–482), CTr2(21–435),
CTr3(21–294), CTr4(21–273); Table 1) identify the GP64
amino acids present in each construct (Table 1 and Fig. 2A, left
panel). GP64 is a 512 amino acid protein that is processed by
signal peptide cleavage after amino acid 20, and the mature
form of wild-type GP64 consists of amino acids 21–512. Thus,
the mature form of C-terminal deletion construct CTr1(21–482)
is comprised of amino acids 21–482 from GP64, plus a C-
terminal V5 epitope and 6His tag sequence. The C-terminally
truncated GP64 protein constructs were metabolically labeled
with 35S-methionine and collected as secreted protein from cell
supernatants. Truncated GP64 proteins were identified directly
by SDS-PAGE of cell supernatants, autoradiography (data not
shown) and by Western Blot analysis of cell supernatants with
an anti-His antibody (Fig. 2B, left panels, top). All constructs
were subjected to immunoprecipitation by AcV1. Representa-
tive results are shown in Fig. 2B (left panels, center), and
additional results are indicated in Table 1. Constructs containing
at least amino acids 21–294 of AcMNPV GP64 were immuno-
precipitated by AcV1, whereas constructs containing amino
acids 21–273 or fewer were not (Fig. 2B, left panel, center;
lanes 5 and 6; Table 1).
Next, we generated a series of N-terminally truncated GP64
protein constructs. Each N-terminally truncated GP64 protein is
truncated from the N-terminus of the mature (cleaved) GP64
protein and contains a c-Myc epitope tag at the N-terminus of the
truncated GP64 protein (Fig. 2A, right panel). EachN-terminally
truncated GP64 construct was cloned under the control of the
AcMNPV GP64 promoter and inserted into an AcMNPV
bacmid containing a gp64 deletion (Lung et al., 2002). Viruses
were propagated in a stable cell line that constitutively expresses
the wild-type OpMNPV GP64 protein as described previously
(Lung et al., 2002; Plonsky et al., 1999). To confirm that the N-
terminal GP64 truncations were transported through the
secretory pathway and localized on the cell surface, the presence
of each truncated GP64 construct at the cell surface was
confirmed by immunofluorescence microscopy. All truncated
proteins indicated in Fig. 4 were detected at the cell surface (data
not shown). N-terminally truncated GP64 proteins were
metabolically labeled with 35S-methionine, and GP64 constructs
containing the AcV1 epitope were immunoprecipitated from cell
lysates with AcV1 (Fig. 2B, right panels, center). To confirm the
presence of each GP64 construct, cell extracts were examined by
Western blot analysis with an anti-c-Myc antibody (Fig. 2B,
Table 1
Summary of the properties of GP64 truncations
C-terminally truncations detected by N-terminally truncations detected by
WB anti-His IP AcV1 Refolding
AcV1
WB anti-His IP AcV1 Refolding
AcV1
CTr1(21–482) + + + NTr1(21–512) + + +
CTr2(21–435) + + + NTr2(125–512) + + +
CTr3(21–294) + + + NTr3(186–512) + + +
CTr4(21–273) + − − NTr4(264–512) + − +
CTr5(21–217) + − − NTr5(271–512) + − +
CTr6(21–157) + − − NTr6(377–512) + – –
CTr7(21–131) + − − NTr7(404–512) + − −
CTr8(21–98) + − − NTr8(459–512) + − −
CTr9(21–58) + − − NTr9(481–512) + − −
WB, western blot. IP, immunoprecipitation. Refolding, refolding assay.
The numbers in parentheses indicate the positions of amino acids covering the peptides.
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tained at least amino acids 186–512 were immunoprecipitated
by AcV1, while constructs containing fewer GP64 sequences
were not (Table 1; Fig. 2B). Thus, by immunoprecipitating
native N- and C-terminally truncated GP64 constructs expressed
in insect cells, the AcV1 epitope was mapped to a 108 amino
acid sequence from 186 to 294 (Fig. 4).
Analysis of refolded GP64 proteins
Because the AcV1 epitope is lost upon denaturation in SDS
and beta-mercaptoethanol, AcV1 does not identify GP64 by
traditional Western blot analysis. However, our prior analysis
showed that loss of AcV1 binding at low pH was restored by
returning the pH to 6.2. We therefore examined the possibility
that the loss of the AcV1 epitope by denaturation in SDS may be
restored by refolding the protein in the absence of SDS. To
address this question, we performed in-gel refolding experi-
ments. Truncated and wild-type GP64 proteins were denatured
in SDS and reduced then electrophoresed in standard polyacryl-
amide gels. GP64 proteins were then refolded by incubating the
gels in a series of buffers containing no SDS (see Materials and
methods) for 30 min then transferring the protein to Immobilon-
P membranes (Millipore) and processing for Western blots by
standard procedures. Blots from gels containing refolded
proteins were challenged with either MAb AcV1 or a control
antibody (anti-c-Myc or anti-6His). Using this in-gel refolding
technique, AcV1 detected N-terminal truncated GP64 proteins
NTr4(264–512), NTr5(271–512), but not NTr6(377–512) and
NTr7(404–512) (Fig. 3 and Table 1). Thus, by refolding GP64,
we were able to map the AcV1 binding site further, to a 24 amino
acid region between amino acids 271 and 294 (Fig. 4).
c-Myc substitutions in the AcV1 epitope
To confirm the location of the AcV1 epitope, we asked
whether substitution mutations in amino acid positions between
271 and 294 would abolish binding of AcV1 to GP64. Two
substitutions of 11 amino acids each were introduced into amino
acid positions 273–284 (substitution Glu273/cmyc) and 277–
288 (substitution Lys277/cmyc), respectively (Fig. 5). In eachcase, an 11 amino acid c-Myc epitope sequence was substituted
for the corresponding 11 amino acids from the GP64 protein.
GP64 constructs that contained substitution mutations Glu273/
cmyc and Lys277/cmyc were then used to generate two recom-
binant AcMNPV viruses in which the wild-type GP64 gene was
deleted and replaced by a GP64 gene containing a substitution
in the AcV1 epitope region. GP64 genes encoding substitution
mutations were inserted into the polyhedrin locus of a gp64-null
AcMNPV genome (Lung et al., 2002). The GP64 proteins
containing the Glu273/cmyc and Lys277/cmyc substitutions
were able to functionally substitute for the wt GP64 protein and
were incorporated into virions at levels similar to that of the wt
GP64 protein (data not shown). Viruses encoding and express-
ing only the Glu273/cmyc or Lys277/cmyc GP64 substitutions
replicated efficiently in Sf9 cells and required no wild-type
GP64 for virus propagation. To determine if the Glu273/cmyc
and Lys277/cmyc substitutions abolished AcV1 binding, GP64
proteins were metabolically labeled with 35S-methionine and
immunoprecipitated with AcV1. While wt GP64 and a control
GP64 (N-terminally c-Myc tagged GP64 NTr(21–512), Fig.
1A) were efficiently immunoprecipitated by AcV1, GP64
proteins containing the Glu273/cmyc and Lys277/cmyc sub-
stitutions were not (Fig. 5, lanes 1 and 2 vs. 3 and 4). As a
control, similar immunoprecipitation experiments were per-
formed using an anti-c-Myc antibody. GP64 control, Glu273/
cmyc, and Lys277/cmyc substitution constructs were immuno-
precipitated by the anti-c-Myc antibody while wt GP64 was not,
as expected (Fig. 5, lanes 6, 7 and 8). Thus, the AcV1 epitope
was mapped to a position between amino acids 271 and 294 and
substitutions of either amino acids 273–284 or 277–288
abolished AcV1 binding. Interestingly, the two viruses contain-
ing the AcV1 substitutions were almost as infectious as wt
AcMNPVon Sf9 cells, with titers of 1.93 × 107 PFU/ml (vAc-
Glu273/cmyc) and 1.73 × 107 PFU/ml (vAc-Lys277/cmyc), as
compared to 1.23 × 108 PFU/ml for wt AcMNPVon Sf9 cells.
However, viruses carrying GP64 proteins with the two
substitutions (Glu273/cmyc and Lys277/cmyc) could not be
neutralized by antibody AcV1 (Fig. 7A). It is also of interest
that another monoclonal antibody known as B12D5 (Keddie et
al., 1989) was previously mapped to a linear epitope in the same
region (amino acids KKRPPTWRHNV at 277–287) (Monsma
Fig. 2. (A) Construction of N- and C-terminally truncated GP64 proteins. The strategy for PCR amplification, subcloning and expression of portions of the GP64 coding
region is shown as diagrams. The strategy for construction of C-terminally truncated constructs is shown on the left and that for construction of N-terminally truncated
constructs on the right. (B) Western blot analysis and immunoprecipitation of C- and N-terminally truncated GP64 proteins (SP, signal peptide; c-Myc, c-Myc tag; V5,
V5 epitope; 6His, 6His tag; TM, transmembrane domain; CTD, cytoplasmic tail domain). Left panel: cells were infectedwith recombinant AcMNPVexpressing secreted
soluble C-terminally truncated GP64 constructs (CTr1(21–482), CTr2(21–435), CTr3(21–294) and CTr4(21–273)). Cells were metabolically labeled with 35S-
methionine for 8 h, and labeled soluble GP64 proteins were harvested from cell supernatants at 72 h pi and prepared as describe in the Materials and methods section.
GP64 was immunoprecipitated with MAb AcV1 and examined by SDS-PAGE (center panel). The top panel shows a Western blot of the cell supernatant preparations
used for immunoprecipitation experiments. GP64 constructs were detected onWestern blots with an anti-6His antibody. Circles (filled or open) represent the positions of
corresponding bands in upper and center panels. Open circles represent the positions of proteins that were not immunoprecipitated by AcV1 (center panel). Gray boxes
(bottom panels) indicate constructs immunoprecipitated by AcV1 and containing the AcV1 epitope. Right panel: cells infected with wild-type or recombinant AcMNPV
constructs and expressing wild-type AcMNPVGP64 or recombinant N-terminally truncated GP64 constructs (NTr1(21–512), NTr2(178–512), NTr3(186–512), NTr4
(264–512) andNTr5(271–512)) weremetabolically labeledwith 35S-methionine for 8 h, and cells were lysed at 72 h pi. GP64was immunoprecipitatedwithMAbAcV1
and examined by SDS-PAGE (center panel). The top panel shows a Western blot of extracts used for immunoprecipitation experiments. On Western blots, GP64
constructs were detected with an anti-c-Myc antibody.
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AcV1 (Fig. 5). The two GP64 substitutions (Glu273/cmyc and
Lys277/cmyc) that abolish AcV1 binding (Fig. 5) also abolish
binding of B12D5 to GP64 (Fig. 6). However, unlike AcV1, we
found that B12D5 was not able to neutralize infectivity of wt
AcMNPV BV (Fig. 7C).
The mechanism of AcV1-mediated inhibition of infectivity
is not known, although prior studies indicate that AcV1 does not
interfere with virion binding at the cell surface (Volkman and
Goldsmith, 1985). If AcV1 binding results in neutralization bysteric hindrance as a result of an antibody molecule occupying
this specific site, we would predict that substitution of this site
by the c-Myc epitope in constructs Glu273/cmyc and Lys277/
cmyc would result in GP64 proteins that would no longer be
neutralized by AcV1 but could be neutralized by an anti-c-Myc
monoclonal antibody. However, in neutralization studies with
viruses carrying the wild-type or substituted forms of GP64
(Fig. 7), we found that, while AcV1 neutralization was indeed
abolished by the Glu273/cmyc and Lys277/cmyc substitutions,
the GP64 proteins carrying the Glu273/cmyc and Lys277/cmyc
Fig. 5. Immunoprecipitation of GP64 protein constructs containing substitutions
in the AcV1 epitope region. The c-Myc epitope sequence was substituted for
GP64 sequences at amino acid positions 273–284 (Glu273/cmyc) and 277–288
(Lys277/cmyc). Cells infected with recombinant AcMNPV viruses expressing
the c-Myc substituted forms of GP64 (replacing wt GP64) were 35S-methionine
labeled and the GP64 constructs examined by immunoprecipitation with either
AcV1 (lanes 1–4) or the anti-c-Myc MAb (lanes 5–8). The diagram (bottom)
shows the locations and sequences of the c-Myc substitutions relative to the
GP64 coding sequence and the mapped AcV1 and B12D5 epitopes. The central
variable domain and conserved domains (black bars) are indicated on the
diagram of the GP64 coding region (SP, signal peptide; TM, transmembrane
domain; CTD, cytoplasmic tail domain).
Fig. 4. Summary of AcV1 epitope mapping. The diagram shows a schematic
representation of the wild-type GP64 ectodomain (top bar) and deletion mutants
of GP64 combined with the results of immunoprecipitation (IP) experiments.
The numbers at the top represent the amino acid positions in the wild-type GP64
protein. Names of the truncated GP64 constructs are indicated on the right, and
the results of IP analyses are summarized on the left (+ or −). The binding site
(epitope) of MAb AcV1 was mapped to a sequence of 108 amino acids (bottom;
amino acids 186–294) with native GP64 proteins and to a sequence of 24 amino
acids (271–294) in protein refolding assays (c-Myc, c-Myc tag; TM, trans-
membrane domain; V5, V5 epitope; 6His, 6His tag; CTD, cytoplasmic tail
domain).
Fig. 3. Western blot analysis of refolded N-terminally truncated GP64
constructs. Protein lysates from cells expressing N-terminal GP64 truncations
were subjected to 10% SDS-PAGE. Proteins were refolded in the acrylamide gel
by incubation in a transfer buffer containing no SDS (see Materials and
methods) for 30 min then transferred onto Immobilon-P membranes (Millipore)
and processed for Western blots by standard procedures. Blots from gels
containing refolded proteins were challenged with either anti-c-Myc (Top
panels) or MAb AcV1 (bottom panels). Open circles represent the positions of
proteins that were not detected by MAb AcV1.
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nal antibody (Figs. 7A and B). Thus, the mechanism of AcV1-
mediated neutralization of GP64 function does not appear to
occur through simple steric hindrance caused by antibody
binding at this site but likely involves a more complex
interaction between AcV1 and GP64 proteins.
Comparison of predicted GP64 proteins from group I NPV
baculoviruses and the related GP75 proteins of the Thogoto-likeFig. 6. Western blot analysis of GP64 protein constructs containing c-Myc
substitutions in the AcV1 epitope region. Lysates of Sf9 cells infected with
either wt AcMNPV (WT) or recombinant viruses expressing GP64 c-Myc
substitution constructs (Glu273/cmyc and Lys277/cmyc) were examined by
Western blot analysis with antibodies AcV5 (top panel), anti-c-Myc (center
panel) or B12D5 (lower panel).
Fig. 7. Neutralization of AcMNPV viruses displaying GP64 protein constructs
with either a wild-type or modified AcV1 epitope region. The graphs show titers
of viruses displaying wild-type AcMNPV GP64 (WT), N-terminally c-Myc
tagged GP64 (NTr1(21–482)) or GP64 proteins with c-Myc substitutions
(Glu273/cmyc and Lys277/cmyc) in the mapped AcV1 epitope. The titer of each
BV preparation was determined by end-point dilution analysis after incubation
with MAb AcV1 (A), anti-c-Myc MAb (B) or MAb B12D5 (C). Each bar
represents the average titer obtained from three separate experiments (mock-
treated represents no antibody treatment).
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the approximately 462 amino acid GP64 ectodomain. In addi-
tion, a non-conserved “central variable domain” of approxi-
mately 118 amino acids is located in the central portion of the
ectodomain (Fig. 5). Epitopes for two monoclonal antibodies
(B12D5 and AcV5) directed against AcMNPV GP64 were
mapped in a prior study (Monsma and Blissard, 1995) (Fig. 5).
Because those antibodies recognized linear epitopes exposed oneither native (B12D5) or denatured (B12D5 and AcV5) GP64, a
simple epitope library screening approach was used previously.
In the current study, we used several approaches to map the
epitope of the neutralizing AcV1 monoclonal antibody. N- and
C-terminal deletion constructs were used to map the AcV1
conformational epitope to a 24 amino acid sequence in the
central variable domain of GP64. Because N- and C-terminally
truncated forms of GP64 were recognized, these data indicate
that additional sequences within the GP64 protein are not
required and that the epitope is included within the 24 amino
acid sequence. Why does AcV1 bind only to the native GP64
protein and not to denatured GP64? One possible explanation is
that the native structure of GP64 may contain a localized pH-
sensitive conformation within this 24 amino acid region, and
this conformation is required for AcV1 binding. Thus, because
AcV1 does not bind in the presence of SDS or at low pH (4.5)
yet maps to a very limited 24 amino acid sequence, we speculate
that AcV1 binding must require a highly localized conformation
of the epitope sequence. Substitution of a c-Myc epitope in two
11 amino acid positions within the 24 amino acid AcV1 epitope
resulted in GP64 proteins that could be functionally substituted
for wild-type GP64 but were not recognized by AcV1. Thus, the
AcV1 epitope sequence per se is not necessary for the function
of GP64. The observation that AcV1 neutralizes infectivity but
does not bind the low pH conformation of GP64 suggests that
AcV1 binding somehow interferes with the low-pH-activated
conformational change. Interestingly, when the c-Myc epitope
was substituted into the AcV1 epitope region, anti-c-Myc did
not neutralize infectivity of the virus. This suggests that the
AcV1-mediated neutralization does not result simply from
steric hindrance, but rather from inhibition of a specific con-
formational change in the GP64 protein.
In a contemporary model for the function of viral membrane
fusion proteins such as Influenza HA and HIV GP41, the
triggering of membrane fusion results in a refolding of the
protein such that a “hairpin” is formed, bringing the distal end of
the fusion protein (containing the hydrophobic fusion domain) in
close proximity to the transmembrane domain (which spans the
viral envelope). Thus, the cellular membrane is placed in close
proximity to the viral envelope membrane. In some cases,
hairpin formation is mediated by the interaction of two alpha
helices. Thus, for trimeric fusion proteins, a “trimer of hairpins”
is believed to form and to generate a six-helix bundle. Expe-
rimental evidence shows that, in such cases, fusion can be dis-
rupted by soluble peptides that encode one of the helices—
presumably inhibiting fusion by competing for the helix–helix
interaction and preventing stable hairpin formation. The
AcMNPV GP64 protein contains a predicted (highly conserved)
amphipathic alpha helix at amino acids 302–345, immediately
downstream of the central variable domain. Prior studies show
that mutations that would disrupt formation of the predicted
helix or the amphipathic nature of the helix also disrupt
membrane fusion by GP64 (Kingsley et al., 1999; Monsma
and Blissard, 1995). In addition, a 29-mer peptide consisting of
amino acids 301 to 329 also disrupted membrane fusion
(Kingsley et al., 1999). These data provide preliminary evidence
for possible participation of the amphipathic alpha helix at 301 in
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position 271–294, immediately upstream of the predicted 301
alpha helix. Thus, we would speculate that, while AcV1 binding
requires a local conformation found in the neutral pH con-
formation of GP64, neutralization of GP64 function (and viral
infectivity) by AcV1 may result from inhibition of a required
conformation change associated with repositioning the alpha
helix or its interacting partner.
Materials and methods
Construction of plasmids and baculoviruses encoding
C-terminally truncated GP64 proteins
A series of plasmids encoding C-terminally truncated GP64
proteins were generated by the following strategy: first, DNA
fragments containing C-terminally truncated GP64 open reading
frames were PCR-amplified from a wild-type (wt) AcMNPV
DNA template. A single forward primer with an EcoRI res-
triction site engineered into the 5′ end (5′-CGG AAT TCC AAG
GCTTCAATAAGGAAC-3′; which included 31 bp of wt gp64
sequence from upstream of the gp64 translation initiation site)
was used in combination with a downstream primer specific for
each truncation (Table 2). Each downstream primer contained an
XbaI site engineered for in-frame insertion of the AcMNPV
gp64 gene into vector pIZ/V5-His (Invitrogen). Thus,EcoRI and
XbaI restriction sites were engineered into to the 5′ and 3′ ends,
respectively, of each PCR product. Each PCR product was
digested with EcoRI and XbaI, purified and ligated into the
EcoRI and XbaI sites of vector pIZ/V5-His to generate a
truncated GP64 ORF fused in-frame at the C-terminus with a V5
and 6His tag.
To generate recombinant baculoviruses expressing the
truncated GP64 proteins, GP64 constructs in pIZ/V5-His were
linearized with ClaI and the ends made blunt with Klenow
(Promega) then digested with EcoRI to excise the fragment
containing the GP64 gene. Truncation-containing fragments
were subcloned into the EcoRI and StuI sites of the pFastBac1
plasmid (Invitrogen). All constructs were confirmed by DNA
sequencing. DH10Bac cells (Invitrogen) were transformed with
the pFastBac1 constructs then selected in kanamycin, genta-Table 2
Primers for N- and C-terminal GP64 truncations
C-terminal GP64 truncations
A single forward primer
5′-CGGAATTCCAAGGCTTCAATAAGGAAC-3′
Reverse primers
CTr1(21–482): 5′-GCTCTAGAGAAGTCAATTTAGCGGCC-3′
CTr2(21–435): 5′-GCTCTAGATCTTTCCAACTGTCGTG-3′
CTr3(21–294): 5′-GCTCTAGACCCTCTGTGTACTTGGCTC-3′
CTr4(21–273): 5′-GCTCTAGACTCTCGACTTTGCGTTTAATGC-3′
CTr5(21–217): 5′-GCTCTAGAGACTTTTGTTTGAGAATC-3′
CTr6(21–157): 5′-GCTCTAGAGTGTGGTGCGCAAAGTG-3′
CTr7(21–131): 5′-GCTCTAGATCGCGAAAACAGTCGTCGC-3′
CTr8(21–98): 5′-GCTCTAGACCCACATTCAGCGTTTTC-3′
CTr9(21–58): 5′-GCTCTAGAGTCTCCACGATGGTGATTTC-3′mycin and tetracycline; and recombinant bacmids were selected
by a color screen. Bacmid DNA was isolated from the single
colony isolates of each construct, and PCR amplification was
used to verify each truncated GP64 construct. Sf9 cells were
subsequently transfected with the bacmid DNAs, and the
resulting viruses were harvested and amplified as described in
the Bac-to-Bac baculovirus expression system manual (Invitro-
gen). Infectious BV titers were determined using an end-point
dilution assay (O'Reilly et al., 1992).
Construction of plasmids and baculoviruses encoding
N-terminally truncated GP64 proteins
N-terminally truncated GP64 constructs were generated in
the following manner. Portions of the GP64 protein (down-
stream from the signal peptide) were PCR-amplified using
primers that contained either an EcoRI site (upstream primer) or
aHindIII site (downstream primer) (Table 2). The resulting PCR
products were digested with EcoRI and HindIII then subcloned
into the EcoRI/HindIII sites of pdFB-gp64sig-cMyc, a pFast-
Bac-derived plasmid containing the gp64 promoter, the signal
peptide and cleavage site followed by a c-Myc epitope tag and a
cloning site (Fig. 2A). Thus, N-terminally truncated forms of
the GP64 gene that are cloned into vector pdFB-gp64sig-cMyc
express a protein that contains the GP64 signal peptide and
cleavage site plus a c-Myc tag. GP64 proteins are therefore
truncated at the N-terminus of the mature GP64 protein, and all
constructs contain an N-terminal c-Myc epitope tag linked by a
Phe residue to a portion of the GP64 protein. Transpositions of
inserts from donor plasmids into the gp64-null bacmid (Lung et
al., 2002) were confirmed by PCR analysis and by DNA
sequencing. Cells stably expressing OpMNPV GP64 (cell line
Sf9Op1D) (Plonsky et al., 1999) were transfected with each
bacmid DNA, and the resulting viruses were harvested from cell
supernatants and titered on Sf9Op1D cells.
Immunofluorescence assay
Sf9 cells (2 × 105 cells/well) were plated in approximately
150 mm diameter wells of 24-well plates (Corning Inc.), and
cells were allowed to attach for 1 h then infected at an MOI ofN-terminal GP64 truncations
A single reverse primer
5′-GAGAAGCTTACATTAATATTGTCTATTACGGTT-3′
Forward primers
NTr1(21–512): 5′-GAGGAATTCGCGGAGCACTGCAACGCGCAA-3′
NTr2(125–512): 5′-GAGGAATTCAGCGACGACTGTTTTCGCGAC-3′
NTr3(186–512): 5′-GAGGAATTCGTATACATTTTGGACGCTGAG-3′
NTr4(264–512): 5′-GAGGAATTCAAAGTCGAGCACCGAGTCAAG-3′
NTr5(271–512): 5′-GAGGAATTCCTGATGCATGCGCACATCAAC-3′
NTr6(377–512): 5′-GAGGAATTCGATTTTAGCAACTACAAGGAA-3′
NTr7(404–512): 5′-GAGGAATTCAGTTGGAAAGATGCCAGCGGC-3′
NTr8(459–512): 5′-GAGGAATTCGGCGGCGTCGGCACCAGTCTG-3′
NTr9(481–512): 5′-GAGGAATTCACTTCGTTCATGTTTGGTCAT-3′
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expressing N-terminally truncated GP64 and incubated for
48 h. Cells were then fixed with 3% paraformaldehyde, a non-
permeabilizing fixative. Cells were washed with phosphate-
buffered saline (PBS, pH 7.4) and then incubated with a
blocking buffer (1% gelatin in PBS, pH 7.4) at 27 °C for 2 h.
After washing with PBS, the cells were incubated with a
primary anti-c-Myc monoclonal antibody (ATCC CRL-1729,
MYC 1-9E10.2; 1:75 dilution in PBS) at 27 °C for 1 h. Cells
were washed 3 times with blocking buffer and incubated with
Alexa fluor 488-anti-mouse (Molecular Probes) at a 1:1000
dilution in PBS at 27 °C for 1 h. After washing 3 times with PBS
(pH 7.4), florescence was observed with an Olympus IX70
fluorescence microscope.
Western blot analysis
Cell lysates were prepared by washing cultured cells with
PBS and resuspending cells in NET buffer (20 mM Tris, pH 7.5,
150 mM NaCl, 0.5% deoxycholate, 1.0% Nonidet P-40, 1 mM
EDTA) to which a protease inhibitor cocktail (Complete; Roche
Applied Science) was added according to the manufacturer's
instructions. NET buffer (50 μl) was added to 1 × 106 cells and
incubated for 30 min at 4 °C, and then nuclei were removed by
pelleting at 4 °C for 10 min at 18,000 × g. For Western blot
analysis, 10 μl of the above cell lysate was mixed with 10 μl of
2× Laemmli buffer (125 mM Tris, 2% sodium dodecyl sulfate,
5% 2-mercaptoethanol, 10% glycerol, 0.001% bromophenol
blue, pH 6.8) and heated to 100 °C for 5 min prior to SDS-10%
polyacrylamide gel electrophoresis (SDS-PAGE). Gels were
blotted onto Immobilon-P membranes (Millipore) and blocked
overnight at 4 °C in TBST (25 mM Tris, pH 7.6, 150 mM NaCl,
0.1% Tween 20, 5% powdered milk). Blots were incubated for
1 h at room temperature with the following primary antibodies
diluted in TBST: AcV5MAb (which recognizes a linear epitope
within AcMNPV GP64) diluted 1:100; anti-His polyclonal
antibody (MBL international) diluted 1:4000; or anti-c-Myc
MAb diluted 1:1000. After washing 3 times in TBST, blots were
incubated with a secondary antibody consisting of a goat anti-
mouse or goat anti-rabbit IgG–alkaline phosphatase conjugate
(Promega) at a dilution of 1:10,000. Western blots were pro-
cessed as described earlier (Blissard and Wenz, 1992).
Protein refolding
For refolding, proteins in the SDS-polyacrylamide gels were
incubated in transfer buffer I (0.01% Triton X-100, 48 mM Tris,
39 mM glycine, 20% methanol, pH 9.2) twice for 15 min and
then transfer buffer II (48 mM Tris, 39 mM glycine, 20%m
ethanol, pH 9.2) twice for 15 min then transferred onto
Immobilon-P membranes (Millipore) in transfer buffer II and
processed by standard procedures for Western blots.
35S-methionine-labeled virions and immunoprecipitation
C-terminal and N-terminal GP64 truncations were labeled
with 35S-methionine and prepared for immunoprecipitation (IP)in the following manner. Sf9 cells (1 × 106 cells/well) were
plated in approximately 35 mm diameter wells of six-well plates
(Corning Inc.). Cells were allowed to attach for 1 h then infected
with either wt AcMNPV or recombinant viruses expressing N-
terminally or C-terminally truncated GP64 at an MOI of 10 or
20 for 1 h. At 29 h post-infection (h pi), the cells were starved by
incubation in 1 ml methionine-free Grace's medium (Invitro-
gen) for 1 h followed by addition of 35S-EasyTag Express
protein labeling mix (1175.0 Ci/mmol, Perkin-Elmer) to a final
concentration of 10 μCi/ml. At 37 h pi, unlabeled methionine
was added to a final concentration of 10 mM and cells were
incubated at 27 °C for an additional 48 h. For C-terminal
truncations, soluble truncated GP64 proteins were harvested
from the supernatant by the following method: cell debris was
removed from the supernatant by centrifugation at 5000 × g for
10 min (Sorvall F20 rotor) then virus was pelleted by centri-
fugation at 100,000 × g for 2 h. Supernatants containing soluble
secreted GP64 proteins were retained for analysis. For N-
terminally truncated GP64 proteins, cell lysates were prepared
by the following methods: cells were washed once with PBS,
then 300 μl NET buffer was added and incubated for 20 min on
ice to lyse cells. Cell lysates (50 μl) in NET buffer were
precleared by adding 50 μl of 10% rabbit serum (Sigma) and
50 μl of a 10% slurry of Protein A Sepharose (Sigma) in NET
buffer and incubating with agitation for 1 h at 4 °C. After
centrifuging (14,000 × g, 5 min), the supernatant was retained
and MAb AcV1 (100 μl) was added to each precleared lysate
along with 50 μl of a 50% slurry of Protein G Agarose (Pierce).
The mixture was incubated overnight at 4 °C with continuous
gentle rocking. Immunoprecipitates were collected by centrifu-
gation (14,000 × g, 5 min) and washed twice with NET buffer.
The precipitated material was solubilized by heating for 5 min at
95 °C in Laemmli buffer and analyzed by electrophoresis on
10% SDS-PAGE gels. Labeled proteins were visualized by
imaging on phosphorImager screens.
Low pH treatments
To examine AcV1 binding to GP64 under various condi-
tions, wild-type or recombinant GP64 constructs were meta-
bolically labeled with 35S-methionine as described above,
exposed to various pH treatments, then immunoprecipitated.
The Sf9 cells (1 × 106 cells) were lysed in 0.5 ml of NET buffer
followed by a 30 min agitation at 4 °C. The lysate was cleared of
the detergent-insoluble material by centrifugation for 30 min at
90,000 × g at 4 °C. The cell lysates were subjected to the
following treatments: (1) low pH only; lysates were adjusted to
pH 4.5 by addition of PBS (pH 1.7), (2) no pH change (pH 6.2)
and (3) low pH treatment followed by readjusting to pH 6.2
[(pH was shifted to pH 4.5 by adding PBS (pH 1.7), incubating
for 30 min at pH 4.5 then readjusting the pH to 6.2 by adding
PBS (pH 12)]. GP64 proteins were then immunoprecipitated
from lysates directly using AcV1 (as described above) or a
control anti-c-Myc MAb.
To examine the effects of low pH treatment on BV infectivity,
AcMNPV BV were exposed to various pH values and then
examined for changes in infectivity. Wild-type AcMNPV BV
Table 3
Primers for c-Myc substitutions
Glu273/
cmyc
Glu273/cmyc-F:
(5′-GAAGAGGACCTGAATCGCCACAACGTTAGAGCC-3′)
Glu273/cmyc-R:
(5′-TGAGATGAGTTTTTGTTCGACTTTGCGTTTAATGCA-3′)
Glu273-F: (5′-CGCCACAACGTTAGAGCC-3′)
Glu273-R: (5′-GACTTTGCGTTTAATGCA-3′)
Lys277/
cmyc
Lys277/cmyc-F:
(5′-GAAGAGGACCTGAATAGAGCCAAGTACACAGAG-3′)
Lys277/cmyc-R:
(5′-TGAGATGAGTTTTTGTTCGACTCGGTGCTCGACTTT-3′)
Lys277-F: (5′-AGAGCCAAGTACACAGAG-3′)
Lys277-R: (5′-GACTCGGTGCTCGACTTT-3′)
Overlapping c-Myc sequences are underlined.
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Grace's medium (pH 2.1) to 1 ml of a virus (BV) stock super-
natant (pH 6.2, 2.18 × 108 PFU/ml). The virus was incubated for
30 min at the adjusted pH at room temperature. Virus prepa-
rations were then readjusted to pH 6.2 by the addition of 600 μl
PBS (pH 12.3) or Grace's medium (pH 9.6), respectively. The
titer of the virus from each treatment was determined by end-
point dilution assay.
Site-directed mutagenesis
c-Myc substitutionmutations weremade by replacing 33 nt in
the GP64 ORF with 33 nt of sequence encoding the c-Myc
epitope: 5′-GAA CAA AAA CTC ATC TCA GAA GAG GAT
CTG AAT-3′. The substitutions were generated by the site-
directed, ligase-independent mutagenesis method (Chiu et al.,
2004). First, a DNA fragment containing the AcMNPV GP64
promoter and an open reading frame were PCR-amplified from a
wild-type AcMNPVDNA template using primers that contained
a KpnI site (upstream primer) or a HindIII site (downstream
primer). The PCR product was digested with KpnI and HindIII
and subcloned into the KpnI and HindIII sites of pGEM-3Z
(Promega). The resulting plasmid DNA contained 211 nt up-
stream of the gp64 ORF, the gp64 ORF, and 13 nt downstream of
the gp64 ORF and was designated pGEM-gp64 and used for the
subsequent inverse PCR. Each c-Myc substitution required four
primers for a single inverse PCR reaction. Two primers were
designed to introduce c-Myc sequence into the 5′-adapter tail of
primers (Table 3). Following amplification, the resulting PCR
mixtures were purified with Qiaex II resins (Qiagen), digested
with DpnI and then hybridized using two cycles of 65 °C for
5 min and 30 °C for 15 min to generate the plasmid containing
the substitution mutation. An aliquot of 3 μl of the purified PCR
reaction was used to transform electrocompetent E. coli TOP10
cells. Clones were screened and recombinants identified by
colony PCR analysis. The mutated gp64 constructs were excised
from the pGEM-gp64 by digestion with KpnI and HindIII and
subcloned into the KpnI and HindIII sites of the pFastBac1
plasmid (Invitrogen). All constructs were confirmed by DNA
sequencing then used for transposition into a gp64-null
AcMNPV genome. Bacmid DNAs were transfected into Sf9
cells, and the resulting viruses, vAc-Glu273/cmyc and vAc-
Lys277/cmyc, were harvested and amplified as described in theBac-to-Bac baculovirus expression system manual (Invitrogen).
Infectious BV titers were determined on Sf9 cells using an end-
point dilution assay (O'Reilly et al., 1992).
Neutralization assay
Previously, it was demonstrated that concentrations of≥2 μg
AcV1 per 106 PFU of AcMNPV BV were sufficient for
neutralization. In the current study, we used excess concentra-
tions of MAb (4.87–71 μgMAb per 106 PFU AcMNPV BV). A
volume of 30 μl wt AcMNPV budded viruses (1.23 × 108 PFU/
ml), NTr1(21–512) (3 × 107 PFU/ml), vAc-Glu273/cmyc
(1.93 × 107 PFU/ml) and vAc-Lys277/cmyc (1.73 × 107 PFU/
ml) were diluted to a total volume of 40 μl with PBS (pH 6.2)
containing either AcV1 (24 μg), anti-c-Myc (18 μg), B12D5
(antibody ascites, 37 μg) or normal mouse IgG (25 μg) and
incubated for 1 h at 27 °C. Titers of the treated and untreated
virus mixtures were determined by end-point dilution assay as
described previously (O'Reilly et al., 1992; Volkman and
Goldsmith, 1985).
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